Application of common turnip polysaccharide in preparation of products for preventing alcoholic liver injury and assisting in dispelling effects of alcohol

Abstract

The invention discloses application of common turnip polysaccharide in preparation of a product for preventing alcoholic liver injury and assisting in dispelling the effects of alcohol, and belongs to the technical field of natural product development and biological medicine. The common turnip polysaccharide prepared through ultrasonic and alcohol extraction is rich in galactose and rhamnose, has high galacturonic acid content, shows typical RG-I type pectic polysaccharide characteristics, can be kept stable in simulated gastrointestinal fluid and directly reaches the colon to play a role; meanwhile, the prepared common turnip polysaccharide can remarkably reduce transaminase increase and lipid accumulation caused by alcohol, and by specifically proliferating beneficial bacteria such as Akkermansia and the like, the intestinal barrier is repaired, and endotoxin is prevented from entering blood; meanwhile, liver hangover alleviating enzymes can be obviously activated, and the drunkenness time is shortened.

Description

Technical Field

[0001] This invention relates to the application of coriander root polysaccharide in the preparation of products for preventing alcoholic liver damage and assisting in the detoxification of alcohol, and belongs to the fields of natural product development and biomedicine. Background Technology

[0002] With the fast pace of life and frequent social interactions, alcohol consumption continues to rise, and the incidence of alcoholic liver disease is also increasing year by year, becoming a global public health problem. Currently, clinical treatments for alcoholic liver injury mainly include abstinence from alcohol, nutritional support, and drug therapy. However, existing drugs often have limited efficacy, significant side effects, or are expensive, and most focus on treating existing liver damage, with limited effectiveness in prevention and aiding in detoxification. Therefore, developing natural, safe, and highly effective products with functions of preventing alcoholic liver injury and aiding in detoxification has significant practical and social value.

[0003] Wild celery root, belonging to the Brassicaceae family and the Brassica genus, is widely cultivated in Xinjiang, Tibet, and other regions of my country as a dual-purpose resource for both medicinal and edible purposes. Current technologies largely focus on simple crude extracts of wild celery root, lacking detailed structural characterization of its active polysaccharide components (especially regarding the preservation of the RG-I type pectin region). More importantly, existing research rarely addresses the deeper mechanisms by which wild celery root polysaccharides protect the liver by regulating the intestinal microecology and repairing the intestinal barrier through the gut-liver axis, and there is a lack of products on the market that simultaneously offer both acute anti-drunkenness and chronic liver protection benefits.

[0004] Therefore, it is of great research significance to provide a polysaccharide from coriander root with specific structural characteristics, high purity, and dual effects of relieving hangovers and protecting the liver. Summary of the Invention

[0005] To address the aforementioned problems, this invention provides a *Coriander* root polysaccharide with specific structural characteristics, high purity, and dual effects of relieving hangovers and protecting the liver. The polysaccharide prepared by this invention is rich in galactose and rhamnose, and has a high galacturonic acid content, exhibiting typical RG-I type pectin polysaccharide characteristics. It remains stable in simulated gastrointestinal fluid, reaching the colon directly to exert its effects. Simultaneously, it significantly reduces alcohol-induced transaminase elevation and lipid accumulation through specific proliferation. Akkermansia It contains beneficial bacteria that repair the intestinal barrier and block endotoxins from entering the bloodstream; at the same time, it can significantly activate liver enzymes that detoxify alcohol, shortening the time it takes to get drunk.

[0006] The first objective of this invention is to provide the application of coriander root polysaccharide in the preparation of products for relieving hangovers, preventing intoxication, and alleviating hangover symptoms.

[0007] In one embodiment, the coriander root polysaccharide can be prepared by the following method: (1) The rhizomes of the coriander are sliced, dried and then pulverized to obtain coriander powder; the coriander powder is defatted by reflux of ethanol and dried to obtain defatted coriander powder; (2) After mixing defatted coriander root powder with water, ultrasonic extraction was performed, the supernatant was collected by centrifugation and concentrated to obtain a concentrated solution; (3) After mixing the concentrated liquid with anhydrous ethanol, the precipitate was collected by alcohol precipitation, centrifugation, dialyzed and dried to obtain the polysaccharide of the root of the plant.

[0008] In one embodiment, in step (2), defatted coriander root powder is mixed with water at a ratio of 1~2 g: 30~100 mL; the ultrasonic extraction is performed at 50~60℃ and 300~420W for 40~60 min.

[0009] In one embodiment, the volume ratio of the concentrate to anhydrous ethanol in step (3) is 1~5:2~30; the alcohol precipitation is performed at 4~36℃ for 12~36 h.

[0010] In one embodiment, the molecular weight cutoff for dialysis in step (3) is 1000~10000 Da, and the dialysis time is 24~72 h; the drying is vacuum freeze drying at -30~-50℃ for 24~72 h.

[0011] In one embodiment, the product may be food, medicine, health product or nutritional product, and the product uses coriander root polysaccharide as the active ingredient.

[0012] In one embodiment, the drug further contains pharmaceutically acceptable excipients; the excipients refer to conventional drug carriers in the pharmaceutical field.

[0013] In one embodiment, the drug carrier includes one or more of the following commonly used in medicine: fillers, binders, wetting agents, disintegrants, lubricants, and flavoring agents.

[0014] In one embodiment, the excipients include one or more of the following: binders such as cellulose derivatives, alginate, gelatin, and polyvinylpyrrolidone; diluents such as starch, pregelatinized starch, dextrin, sucrose, lactose, and mannitol; fillers such as starch and sucrose; humectants such as glycerin; disintegrants such as sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, and dry starch; absorption promoters such as quaternary ammonium compounds; surfactants such as polysorbates, fatty acid sorbitan, and fatty acid glycerides; colorants such as titanium dioxide, sunset yellow, methylene blue, and pharmaceutical iron oxide red; lubricants such as hydrogenated vegetable oil, talc, and polyethylene glycol; coating materials such as acrylic resins, hydroxypropyl methylcellulose, povidone, and cellulose acetate; and other excipients such as flavoring agents and sweeteners may also be added to the composition.

[0015] In one embodiment, the dosage form of the drug includes, but is not limited to, oral dosage form, injectable dosage form, and inhaled dosage form; Preferably, the oral dosage form includes, but is not limited to, tablets, capsules, granules, oral liquids, and oral suspensions; Preferably, the injectable dosage form includes, but is not limited to, injection solution and injection powder for injection; Preferably, the inhalation dosage form includes, but is not limited to, aerosols and powder inhalers; The health products also contain acceptable excipients.

[0016] Beneficial effects The polysaccharide prepared by this invention is rich in galactose and rhamnose, and has a high galacturonic acid content, exhibiting typical RG-I type pectin polysaccharide characteristics. It can remain stable in simulated gastrointestinal fluid and reach the colon to exert its effect.

[0017] The *Corydalis yanhusuo* polysaccharide prepared by this invention can not only significantly reduce alcohol-induced transaminase elevation and lipid accumulation, but also promote specific proliferation. Akkermansia It contains beneficial bacteria that repair the intestinal barrier and block endotoxins from entering the bloodstream; at the same time, it can significantly activate liver enzymes that detoxify alcohol, shortening the time it takes to get drunk. Attached Figure Description

[0018] Figure 1 The molecular weight (Mw, ×10⁻¹⁰) of coriander root polysaccharide during in vitro simulated digestion. 5 Da) change; Figure 2 The effect of coriander root polysaccharide on the righting reflex in mice; Figure 3 Effects of coriander root polysaccharide on the activity of hepatic alcohol-degrading enzymes Figure 4 The results are for liver function and lipid metabolism indicators. Figure 5 The results of liver antioxidant index testing; Figure 6 Results of intestinal barrier and inflammatory marker testing; Figure 7 The relative abundance (%) of key beneficial bacteria genera in the mouse gut. Detailed Implementation

[0019] The present invention will be further described below with reference to the accompanying drawings and specific embodiments. These embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Experimental methods in the following embodiments, unless otherwise specified, are generally performed under conventional conditions in the art. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those familiar with the art.

[0020] Raw material source: The coriander root was purchased from Nangqian County, Yushu Tibetan Autonomous Prefecture.

[0021] Solution preparation: The formulations of the simulated oral, gastric, and small intestinal fluids involved in the embodiments are shown in Table 1: Table 1

[0022] Among them, KCl, KH2PO4, NaHCO3, NaCl, MgCl2(H2O)6, (NH)4CO3, and CaCl2(H2O)2 were purchased from Sinopharm Chemical Reagent Co., Ltd.

[0023] The measurement methods involved in the examples are as follows: 1. Determination of weight-average molecular weight of polysaccharides The HPSEC-MALS-RI method is an advanced coupled technique for determining the absolute weight-average molecular weight (Mw) and molecular weight distribution (MWD) of polysaccharides. The procedure is as follows: First, the polysaccharide from *Gynostemma pentaphyllum* is completely dissolved in a specific buffered mobile phase (0.1M NaNO3 solution) and filtered through a 0.22 μm filter membrane. The solution is then injected into a high-performance size exclusion chromatography (HPSEC) system. A column packed with porous gel is used for separation based on molecular fluid dynamics volume. The separated components sequentially pass through a multi-angle laser light scattering (MALS) detector and a differential refractive index (RI) detector. MALS measures the light scattering intensity of each eluted component at different angles in real time, while RI simultaneously determines its concentration. Finally, using dedicated software, the two signals are combined. Based on the fundamental equation of light scattering, and given the known sample refractive index increment (dn / dc value) and laser wavelength, a complete molecular weight distribution curve and accurate weight-average molecular weight (Mw) are obtained.

[0024] 2. Measurement of righting reflex In a quiet, temperature-controlled experimental environment, mice are gently and quickly placed supine on a flat surface, and timing is started immediately. The mice are continuously observed to see if they can roll back to a prone position by coordinating the movement of their limbs within a set time. The time required for them to successfully roll back (latency period) and whether they have recovered are accurately recorded. After the test, it is ensured that the mice have fully recovered. This process is used to quantitatively assess the degree of inhibition or damage to neuromotor function by prolonging the righting latency period or losing the reflex.

[0025] 3. Collection of serum and liver samples After the final alcohol gavage treatment, the mice were fasted (with free access to water) for 9 h. Whole blood was collected in 1.5 mL EP tubes by ocular blood collection and allowed to stand at room temperature for 1 h. Subsequently, the tubes were centrifuged at 4 ℃ and 3000 r / min for 10 min, and the supernatant serum was separated. The mice were then sacrificed, and their livers were harvested, aliquoted, and stored in an ultra-low temperature freezer at -80 ℃ for later use.

[0026] 3. Methods for determining the activity of liver alcohol-degrading enzymes For ADH and ALDH assays, liver tissue was collected and homogenized with pre-cooled homogenizing medium (e.g., 0.15M KCl~0.1M sodium phosphate buffer, pH 7.4) at a weight-to-volume ratio of 1:9. The mixture was homogenized on ice and centrifuged at 10,000×g for 15 minutes at 4°C. The supernatant was used as the enzyme source and stored on ice for later testing. For ALDH assays, an ADH inhibitor was added. The reaction mixture (containing glycine-sodium pyrophosphate buffer (pH 9.0) and NAD+) was added to the cuvette. + Mix the sample supernatant with the solution, preheat at 37°C for 3 minutes, add the ethanol substrate (high-concentration ethanol solution), and quickly and gently invert 2-3 times to mix. Immediately place in a spectrophotometer preheated to 37°C and measure at 340°C. nm At the specified wavelength, continuously monitor the rise in absorbance (OD value) for 3-5 minutes, and record the change in absorbance per minute (ΔA / min) during the linear segment. ADH activity = (ΔA / min) × (total reaction volume × 1000) / (NADH millimolecular extinction coefficient × sample volume × protein concentration).

[0027] 4. Methods for measuring liver function and lipid metabolism ALT and AST assays: Take fresh, non-hemolyzed serum or plasma, place on ice, add substrate buffer (containing alanine and α-ketoglutarate) to the cuvette / reaction well, add the sample, mix well, and incubate precisely at 37°C for 5 minutes. Add NADH starting solution, mix immediately, and immediately place in the instrument. Incubate at 340°C. nm The absorbance was continuously monitored for a decrease over 3 minutes at the specified wavelength, and the change per minute (ΔA / min) was recorded. The ALT activity (U / L) was calculated as (ΔA / min) × (total reaction volume × 1000) / (millimolar extinction coefficient × sample volume × optical path).

[0028] Determination of TG and TC: Take fresh, non-hemolyzed serum or plasma, add an appropriate amount of working solution and sample (or standard / blank) at a ratio (e.g., 1000:10 μL) to a cuvette / reaction well, mix thoroughly, and incubate at 37°C for 10-15 minutes. Measure the OD value at a dominant wavelength of 500 nm (secondary wavelength as above). Calculate the factor F or plot a standard curve based on the calibrator concentration and its OD value, and substitute into the formula: TG / TC concentration = sample OD value × F (or find the value from the curve).

[0029] LDL-C assay: Fresh, non-hemolyzed serum or plasma is added to reagent R1 (containing surfactants such as cholesterol esterase / oxidase), incubated for 5 minutes to remove interference from non-LDL lipoproteins, then reagent R2 (containing surfactant 2, chromogen, etc.) is added to initiate the specific colorimetric reaction of LDL-C. After adding R2 and mixing, the mixture is incubated at 37°C for 5 minutes, and the reaction is performed at a main wavelength of 500-600 nm.nm (subwavelength 700) nm The absorbance was measured under a standard curve, and the LDL-C concentration of the sample was directly calculated based on the absorbance value of the calibrator measured along with it, using the standard curve or coefficient K.

[0030] 5. Liver antioxidant capacity assay SOD, GSH-PX, and MDA were measured using the WST-8 method SOD kit, GSH-PX kit, and MDA detection kit, respectively.

[0031] SOD was used to prepare a 10% tissue homogenate with pre-cooled PBS. After centrifugation, the supernatant was collected and the sample, WST-8 working solution, and enzyme starter solution were added sequentially. After mixing, the mixture was incubated at 37°C in the dark for 30 minutes. The homogenate was then read using a microplate reader at 450 nm. nm The absorbance (OD value) of each well was measured at the specified wavelength.

[0032] Prepare tissue homogenate supernatant using GSH-PX1 as described above. Add GSH, sample, and peroxide (e.g., Cummene Hydroperoxide) sequentially to initiate the reaction. React at 37°C for 5 minutes. Add metaphosphate to precipitate proteins. After centrifugation, collect the supernatant and add DTNB chromogenic solution. Incubate at room temperature for 15 minutes. Then, at 412°C... nm OD value is measured at wavelength.

[0033] Prepare the MDA homogenate supernatant as described above (or use serum directly). Mix the sample with an equal volume of TBA working solution, heat in a boiling water bath or 95°C metal bath for 40 minutes, cool under running water, centrifuge to collect the supernatant, and then... nm The OD value of the supernatant was measured at a specific wavelength. Finally, the content was calculated based on the respective standard curves. 6. Intestinal barrier and inflammation suppression LPS determination mainly employs an endpoint colorimetric method based on the Limulus Amebocyte Lysate (LAL) coagulation reaction. The sample is diluted with pyrogen-free water and incubated with LAL at 37°C for 10–30 minutes. The chromogenic substrate is then added, and the reaction is terminated after incubation. 405 nm Measure absorbance and calculate concentration using a standard curve; protein levels of TNF-α, ZO-1, and Occludin are detected using enzyme-linked immunosorbent assay (ELISA). Follow the ELISA kit instructions: add samples (standards / samples), add biotinylated antibody, add HRP-streptavidin, add TMB for color development, incubate in the dark for 15-30 minutes, add stop solution, and incubate at 450°C within 30 minutes. nm Measure the absorbance and calculate the concentration using a standard curve.

[0034] 7. Intestinal flora detection Bacterial genomic DNA was extracted from fecal samples using the TIANAMP Fecal DNA Kit (DP328, TIANGEN, China). Library preparation was performed using the NEBNext® Ultra™ DNA Library Preparation Kit (New England Biolabs, USA) on an Illumina NovaSeq 6000 platform, with paired-end sequencing (2 × 150 bp). Raw sequencing reads were quality filtered using Trimomatic to remove adapters and low-quality bases. Host-derived reads were removed by aligning the sequences to a human reference genome using Bowtie 2. Initial assignment was performed using Kraken 2, followed by species-level abundance estimation using Bracken. All 16S rDNA analyses, including quality control, taxonomic annotation, and abundance analysis, were performed by Shenzhen MicroMed Technology Group Co., Ltd.

[0035] Example 1: Extraction and purification of coriander root polysaccharide (MJP) The extraction and purification steps of coriander root polysaccharides are as follows: (1) Raw material pretreatment: Take fresh coriander rhizomes, wash, slice, dry at 50°C and then pulverize through a 60-mesh sieve to obtain coriander powder; the coriander powder is defatted by reflux of 95% ethanol to remove fat-soluble impurities and monosaccharides, and then air-dried to obtain defatted coriander powder.

[0036] (2) Extraction: The defatted coriander root powder was mixed with distilled water at a ratio of 1 g: 43 mL, and extracted by ultrasonication at 360 W at 60°C for 55 min. After centrifugation at 5000 r / min for 10 min, the supernatant was collected to obtain the extract. The extract was concentrated under reduced pressure to 1 / 4 of the original volume to obtain the concentrate.

[0037] (3) Purification: Add anhydrous ethanol to the concentrate to make the final concentration of the concentrate reach 20% (v / v), let it stand overnight at 4°C for alcohol precipitation, and collect the precipitate by centrifugation; after redissolving the precipitate with water, put it into a dialysis bag (molecular weight cutoff 3500 Da), and dialyze with running water for 48 hours to remove small molecule impurities; freeze-dry the obtained dialysis solution to obtain active coriander root polysaccharide, which is named MJP.

[0038] Example 2: Structural characterization of coriander root polysaccharides 1. Monosaccharide composition analysis The monosaccharide composition of *Codonopsis pilosula* root polysaccharide was determined by high performance anion exchange chromatography (HPAEC-PAD). The results are shown in Table 1. The results indicate that *Codonopsis pilosula* root polysaccharide is an acidic heteropolysaccharide mainly composed of galactose and rhamnose.

[0039] Table 1

[0040] 2. Determination of molecular weight The molecular weight of the polysaccharide from the root of *Corydalis yanhusuo* was determined by high-performance gel permeation chromatography (HPGPC). The results showed that the weight-average molecular weight (Mw) of the polysaccharide was 75.3 kDa, with a small polydispersity index and uniform distribution.

[0041] Example 3: In vitro simulated digestion stability of coriander root polysaccharides By establishing an in vitro simulated saliva-stomach-small intestine digestion model and measuring the changes in the weight-average molecular weight (Mw) of polysaccharides during digestion, we can verify whether MJP can pass through the gastrointestinal tract into the colon.

[0042] Model establishment: First, the primary degradation of *Codonopsis pilosula* polysaccharides (MJPs) by the oral cavity was simulated. 50 g of MJPs and 46.6 mg of salivary amylase were mixed in 50 mL of simulated oral fluid (SSF) and stirred in a 37°C water bath at 120 rpm for 2 min to obtain simulated oral digestion products (MJPs). Subsequently, the acidic hydrolysis of *Codonopsis pilosula* polysaccharides by the stomach was evaluated. 90 mL of the simulated oral digestion products were transferred to 90 mL of simulated gastric juice (SGF) containing 133.3 mg of pepsin and 120 mg of gastric lipase. The pH was adjusted to 3.0 (using 0.1 mol / L HCl), and the mixture was stirred in a 37°C water bath at 120 r / min for 3 h. Sample S1 was taken after 1 h of simulated gastric digestion, and sample S3 was taken after 3 h of digestion.

[0043] To assess the terminal digestion effect of *Codonopsis pilosula* polysaccharides in the small intestine, 180 mL of simulated gastric digestion products were mixed with 180 mL of simulated intestinal fluid (SIF) containing 1.33 g pancreatic lipase, 3.22 g bile salts, and 400 mg trypsin. The mixture was kept at pH 6.8 (adjusted with 0.1 mol / L NaOH) and stirred in a 37°C water bath at 120 rpm for 5 h. Samples (I1) were collected 1 h after simulated intestinal digestion, and samples (I5) were collected 5 h later. All samples were inactivated by boiling water for 10 min, cooled, and purified using a dialysis bag with a molecular weight cutoff of 1000 Da for 48 h.

[0044] The weight-average molecular weight of polysaccharides in the digestion products was determined, with untreated MJPs used as a control. Results are as follows: Figure 1 As shown, the results indicate that after treatment in simulated gastric juice (pH 3.0) and small intestinal juice (pH 6.8) for different times, the molecular weight of MJP was not significantly different from that before digestion (P>0.05), indicating that coriander polysaccharide has good anti-digestion properties and can reach the colon in an intact macromolecular form, and be utilized by the intestinal flora as a prebiotic.

[0045] Example 4: The detoxifying effect of coriander root polysaccharide on acute alcohol poisoning An acute alcohol poisoning model was established using C57BL / 6J mice. The mice were randomly divided into 4 groups, with 6 mice in each group: The control group consisted of mice that were given 0.2 mL of physiological saline by gavage, followed by another 0.2 mL of physiological saline by gavage 30 min later. The model group mice were given 0.2 mL of physiological saline by gavage, followed by 0.2 mL of 50% alcohol (v / v) by gavage 30 min later. The positive control group consisted of mice that were administered 0.2 mL of 15 mg / mL biphenyl diester (Bif) by gavage, followed by 0.2 mL of 50% ethanol by gavage 30 min later. The coriander polysaccharide group consisted of mice that were administered 0.2 mL of coriander polysaccharide at a concentration of 30 mg / mL by gavage, followed by 0.2 mL of 50% ethanol by gavage 30 min later. The mice were administered alcohol twice (30 min apart), and the righting reflex was measured 1 h after the last alcohol gavage.

[0046] The results are as follows Figure 2 As shown, the results indicate that the polysaccharide group from the root of the coriander can significantly prolong the latency period of intoxication and shorten the sobering-up time.

[0047] The mice were administered alcohol twice by gavage (30 min apart). One hour after the last gavage, liver samples were collected to measure the activities of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH).

[0048] The results showed that ( Figure 3 ), and the polysaccharide from the root of the coriander significantly activated the activity of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) in the liver, thus accelerating alcohol metabolism.

[0049] Example 5: The effect of coriander root polysaccharide on improving chronic alcoholic liver injury and its repair mechanism and microbiome regulation based on the gut-liver axis. A mouse model of chronic alcoholic liver injury was established using the Lieber-DeCarli liquid diet method, with continuous modeling for 4 weeks.

[0050] C57BL / 6J mouse modeling: Lieber-DeCarli liquid feed (Bio-Serv, Dyets) was purchased from a biotechnology company. During the adaptation period, the feed was gradually switched from solid to alcohol-free control liquid feed.

[0051] The mice were randomly divided into 4 groups of 6 mice each: The control group consisted of mice that were given normal drinking water and food via gavage. The model group consisted of mice fed Lieber-DeCarli liquid diet (containing 5% alcohol (v / v)). The BIf group mice were fed Lieber-DeCarli liquid diet (containing 5% alcohol (v / v)) and were given 0.2 mL of biphenyl diester Bif at a concentration of 15 mg / mL by gavage daily; MJPs mice were fed Lieber-DeCarli liquid diet (containing 5% alcohol (v / v)) and were also given 0.2 mL of coriander root polysaccharide at a concentration of 30 mg / mL by gavage.

[0052] Mice in each group were administered the medication by gavage once daily for 28 consecutive days. Subsequently, serum, liver, and fresh fecal samples were collected from the mice for further analysis.

[0053] 1. Liver function and lipid metabolism Serum and liver samples were collected from the mice mentioned above, and the expression levels of serum ALT, AST, LDL-C, and liver TG and TC were measured. The results are as follows: Figure 4 As shown, the results indicated that serum ALT, AST, and liver TG and TC levels were significantly elevated in the model group, indicating successful model establishment. After intervention with coriander root polysaccharide, the above indicators all decreased significantly, with effects superior to or close to the positive control group (biphenyl diester), and TG and TC levels were even better than those in the normal group, demonstrating excellent lipid metabolism regulation capabilities.

[0054] 2. Liver's antioxidant capacity Liver samples were taken from the mice mentioned above, and the activities of SOD and GSH-Px, as well as the content of MDA, were measured. The results are as follows: Figure 5 As shown, the results indicate that coriander root polysaccharide significantly enhances the activity of SOD and GSH-Px in the liver and significantly reduces the content of lipid peroxidation product MDA.

[0055] 3. Intestinal barrier and inflammation suppression Serum samples were collected from the mice mentioned above, and the protein levels of TNF-α, ZO-1, and Occludin in the serum were measured. The results are as follows: Figure 6 As shown, coriander root polysaccharide significantly reduced serum endotoxin (LPS) levels by repairing intestinal tight junction protein (ZO-1 / Occludin), thereby blocking LPS-induced liver inflammatory response (significantly reducing TNF-α and IL-6).

[0056] 4. Regulation of gut microbiota Fresh feces were collected from the mice mentioned above, and the gut microbiota in the feces was analyzed using 16S rDNA sequencing. 16S rDNA sequencing analysis ( Figure 7 This indicates that alcohol leads to gut microbiota imbalance, with a significant decrease in the abundance of beneficial bacteria. After intervention with coriander root polysaccharides, specific enrichment of beneficial bacteria was observed. Akkermansia (Ackermania) Muribaculaceae and butyric acid producing bacteria ( Lachnospiraceae(NK4A136 group), these bacteria are closely related to intestinal barrier repair and anti-inflammation. Intervention with coriander root polysaccharides selectively enriched beneficial species and suppressed potentially pathogenic species, indicating targeted reorganization of the gut microbiota, which may contribute to its hepatoprotective effects.

[0057] Although the present invention has been disclosed above with reference to preferred embodiments, it is not intended to limit the present invention. Anyone skilled in the art can make various modifications and alterations without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be determined by the claims.

Claims

1. Application of coriander root polysaccharide in the preparation of products for relieving hangovers, preventing drunkenness, and alleviating hangover symptoms.

2. The application according to claim 1, characterized in that, The polysaccharide from the coriander root can be prepared by the following method: (1) The rhizomes of the coriander are sliced, dried and then pulverized to obtain coriander powder; the coriander powder is defatted by reflux of ethanol and dried to obtain defatted coriander powder; (2) After mixing defatted coriander root powder with water, ultrasonic extraction was performed, the supernatant was collected by centrifugation and concentrated to obtain a concentrated solution; (3) The concentrated liquid was mixed with anhydrous ethanol, precipitated by alcohol precipitation, centrifuged to collect the precipitate, dialyzed and dried to obtain the polysaccharide of the root of the plant.

3. The application according to claim 2, characterized in that, In step (2), defatted coriander root powder is mixed with water at a ratio of 1~2 g: 30~100 mL; the ultrasonic extraction is performed at 50~60℃ and 300~420W for 40~60 min.

4. The application according to claim 2, characterized in that, In step (3), the volume ratio of the concentrate to anhydrous ethanol is 1~5:2~30; the alcohol precipitation is performed at 4~36℃ for 12~36 h.

5. The application according to claim 2, characterized in that, The molecular weight cutoff for dialysis in step (3) is 1000~10000 Da, and the dialysis time is 24~72 h; the drying is vacuum freeze drying at -30~-50℃ for 24~72 h.

6. The application according to claim 1, characterized in that, The product may be food, medicine, health product or nutritional product, and the product uses coriander root polysaccharide as the active ingredient.

7. The application according to claim 6, characterized in that, The drug also contains pharmaceutically acceptable excipients; the excipients refer to conventional drug carriers in the pharmaceutical field.

8. The application according to claim 7, characterized in that, The drug carrier includes one or more of the following commonly used in medicine: fillers, adhesives, wetting agents, disintegrants, lubricants, and flavoring agents.

9. The application according to claim 7, characterized in that, The excipients include one or more of the following: binders such as cellulose derivatives, alginate, gelatin, and polyvinylpyrrolidone; diluents such as starch, pregelatinized starch, dextrin, sucrose, lactose, and mannitol; fillers such as starch and sucrose; humectants such as glycerin; disintegrants such as sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, and dry starch; absorption promoters such as quaternary ammonium compounds; surfactants such as polysorbates, fatty acid sorbitan, and fatty acid glycerides; colorants such as titanium dioxide, sunset yellow, methylene blue, and pharmaceutical iron oxide red; lubricants such as hydrogenated vegetable oil, talc, and polyethylene glycol; coating materials such as acrylic resins, hydroxypropyl methylcellulose, povidone, and cellulose acetate; and other excipients such as flavoring agents and sweeteners may also be added to the composition.

10. The application according to claim 6, characterized in that, The dosage forms of the medicine include, but are not limited to, oral dosage forms, injectable dosage forms, and inhaled dosage forms; Preferably, the oral dosage form includes, but is not limited to, tablets, capsules, granules, oral liquids, and oral suspensions; Preferably, the injectable dosage form includes, but is not limited to, injection solution and injection powder for injection; Preferably, the inhalation dosage form includes, but is not limited to, aerosols and powder inhalers; The health products also contain acceptable excipients.

Images